|
Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review. |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate |
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech |
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi |
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology |
|
|
Honoraria - Medivation; Novartis |
Consulting or Advisory Role - Aveo; Myriad Pharmaceuticals; Novartis; Pfizer |
Research Funding - Medivation |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis (Inst) |
Research Funding - Novartis (Inst) |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Pfizer |
Research Funding - Exelixis; GlaxoSmithKline; Novartis; Onyx; Pfizer |
Travel, Accommodations, Expenses - GlaxoSmithKline; Novartis; Pfizer |